A Phase IIa Clinical Study to Evaluate KAND567 against Cardiovascular Inflammation Associated with Myocardial Infarction in Patients Suffering from Myocardial Infarction
Phase of Trial: Phase II
Latest Information Update: 09 Feb 2019
At a glance
- Drugs KAND-567 (Primary)
- Indications Cardiovascular disorders; Inflammation
- Focus Therapeutic Use
- Sponsors Kancera
- 09 Feb 2019 According to a Kancera media release, the company plans to start this trial in the second half of 2019.
- 07 Dec 2018 According to a Kancera website, the company plans to start a phase 2 study of KAND 567 in Cardiovascular disorders.
- 07 Dec 2018 New trial record